Lower HCRU and costs may be reflective of improved patient care.

Biocartis Group of Companies (“Biocartis”), an innovative molecular diagnostics company, is pleased to announce that its Idylla™ CDx MSI Test developed in partnership with Bristol Myers Squibb, has ...

LONDON, GREATER LONDON, UNITED KINGDOM, September 15, 2025 /EINPresswire.com/ -- What Is The Expected Cagr For The Syndromic Multiplex Diagnostics Market Through 2025? The market size for syndromic ...

It's unclear what implications the vote will have for insurance coverage for Americans who want to receive a COVID-19 vaccine ...

Thermo Fisher Scientific TMO recently announced the launch of the Olink Target 48 Neurodegeneration panel — a ...

Government is drafting a regulatory framework for India's booming coaching industry, starting with a crackdown on misleading ...

HOLX's global push shows strength, with surgical growth and rising diagnostics use offsetting near-term challenges.

The latest update is out from Pacific Edge Limited ( (PFGTF) ).

Rare pathogenic variants in cancer predisposition genes increase the risk of developing single and multiple primary cancers, researchers found.